2017-LB: Inpatient Use of Dexcom Continuous Glucose Monitoring—Insights from the Dexcom Hospital Registry

Abstract

Introduction and Objective: Although continuous glucose monitoring (CGM) is not indicated for inpatient use, the COVID-19 pandemic provided opportunities for hospital use beyond clinical trials. This analysis explored adult use from the Dexcom Hospital Registry, a database of real-world inpatient CGM use. Methods: This retrospective analysis included two US sites (ICU and non-ICU). Demographics, point-of-care (POC) blood glucose test frequency before and during CGM (Dexcom G6) wear, site-based glycemic metrics, and other hospital metrics were analyzed. Results: At Site 1, there were 613 G6 encounters (438 ICU encounters: mean age 61 years, 73% type 2 (T2D), 58% male) from April 2020 to December 2022. At Site 2, there were 751 G6 encounters (712 non-ICU encounters: mean age 65 years, 85% T2D, 55% male) from May 2020 to October 2022. Mean daily POC frequency decreased from 5.9 ± 4.2 before G6 use to 4.1 ± 2.3 with G6 use at Site 1 and from 3.5 ± 1.1 to 2.5 ± 0.9 at Site 2 (all p<0.001). Time <70 mg/dL was <1% at both sites. Time >180 mg/dL was 29.6% at Site 1 and 51.7% at Site 2 (Table). Conclusion: There was a statistically significant reduction in mean daily POC frequency and minimal hypoglycemia during G6 wear. An opportunity exists for hospitals to establish treat-to-target protocols using CGM to address hyperglycemia, minimize hypoglycemia, and reduce burden from POC testing. Disclosure F. Howell: Employee; Dexcom, Inc. E. Christina: Employee; Dexcom, Inc. Y. Xu: Employee; Dexcom, Inc. X. Wang: None. L. Yang: Employee; Dexcom, Inc. N. Nigro: Employee; Dexcom. J.K. Chow: Employee; Dexcom, Inc. A. Jbaily: Employee; Dexcom, Inc. A. Philis-Tsimikas: Advisory Panel; Dexcom, Inc. Research Support; Dexcom, Inc. Advisory Panel; Lilly Diabetes. Research Support; Lilly Diabetes. Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk. Advisory Panel; Medtronic, Sanofi. K.L. Good: None. V.M. Snell: None.